23-epi-26-Deoxyactein 27-Deoxyactein|cas:501938-01-8|西域试剂

23-epi-26-Deoxyactein 27-Deoxyactein

产品编号：Bellancom-139058| CAS NO：501938-01-8| 分子式：C₃₇H₅₆O₁₀| 分子量：660.83

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	包装	价格	库存与货期	购买量	操作
Bellancom-139058		￥7800.00	杭州北京（现货）
Bellancom-139058		￥12500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

23-epi-26-Deoxyactein 27-Deoxyactein

产品介绍

23-epi-26-Deoxyactein 是天然的、具有口服活性的抗肥胖和抗肿瘤作用的化合物。

生物活性

23-epi-26-Deoxyactein is a natural and orally active anti-obesity and anti-cancer compound.

体外研究

23-epi-26-Deoxyactein (DA :10 μM and 20 μM) inhibits 3T3-L1 adipogenesis through down-regulating the expression of C/ebpα, C/ebpβ, and Pparγ, which are the critical adipogenic transcription factors.
23-epi-26-Deoxyactein (DA) promotes mitochondrial biogenesis in pancreatic β-cells preventing methylglyoxal-induced oxidative cell damage and protects osteoblasts against Antimycin A-induced cell damage.
23-epi-26-Deoxyactein (DA) inhibits growth of the MCF7 human breast cancer cells and induces cell cycle arrest at G1 (IC₅₀ of 21μM).
23-epi-26-Deoxyactein (0.1-1 μM) protects osteoblasts against Antimycin A-induced cell damage^[4].

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Differentiation Assay

Cell Line:	3T3-L1 preadipocytes.
Concentration:	0-50 μM.
Incubation Time:	8 days.
Result:	10 μM DA inhibited the adipogenesis of 3T3-L1 preadipocytes mainly at the early stage of differentiation.

体内研究
(In Vivo)

23-epi-26-Deoxyactein (DA: 5 and 10 mg/kg/d) significantly lowers body weight gain, fat mass, and liver weight in HFD-fed mice. 23-epi-26-Deoxyactein (DA) also reduces insulin resistance and serum lipoprotein levels in HFD-fed mice.
23-epi-26-Deoxyactein (DA) promotes adipocyte lipolysis in mice through activating the AMPK signaling and SIRT1-FOXO1 pathway.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Diet induced obesity in C57BL/6 mice.
Dosage:	1-10 mg/kg.
Administration:	Orally, daily for 12 weeks.
Result:	Lowered body weight gain, fat mass, and liver weight. 5 mg/kg/d DA significantly improved HFD-induced glucose intolerance.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Diet induced obesity in C57BL/6 mice.
Dosage:	1-10 mg/kg.
Administration:	Orally, daily for 12 weeks.
Result:	Lowered body weight gain, fat mass, and liver weight. 5 mg/kg/d DA significantly improved HFD-induced glucose intolerance.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Diet induced obesity in C57BL/6 mice.
Dosage:	1-10 mg/kg.
Administration:	Orally, daily for 12 weeks.
Result:	Lowered body weight gain, fat mass, and liver weight. 5 mg/kg/d DA significantly improved HFD-induced glucose intolerance.